FREMANEZUMAG (FREMANEZUMAB DAN MAGNESIUM) SEBAGAI INOVASI DALAM PENCEGAHAN SERANGAN MIGRAIN

Putri Windiana Rahman, Safira Qalbissilmi

Abstract


Migrain adalah penyakit yang dirasakan seumur hidup, sering berulang dan menghambat aktivitas penderitanya. Patogenesis migrain dispekulasikan berada pada sistem trigeminal dengan aktivitas neurotransmitter seperti CGRP, glutamat, serotonin dan nitrit oksida, vasodilatasi arteri serebri serta inflamasi neurogenic. Tata laksana migrain dengan konsumsi triptan didapatkan efek samping yang tak terduga antara penggunaan obat tersebut dengan kejadian iskemik serebrovaskular, jantung coroner dan hipertensi berat. Saat ini, telah ditemukan tata laksana terbaru dan sudah diakui untuk penyakit migrain. Pengobatan yang berhubungan dengan CGRP dan senyawa magnesium menawarkan manfaat yang cukup besar dibandingkan obat-obatan yang sudah ada. 


Keywords


migrain, inovasi pengobatan migrain, calcitonin gene- related peptide (CGRP), magnesium

Full Text:

PDF

References


M. Kurniawan Isti SR. Acuan Panduan Praktik Klinis Neurologi. Jakarta: Perhimpunan Dokter Spesialis Saraf Indonesia; 2014.

Michael Teixido MD. Migraine - more than a Headache. Hopkins Medicines; 2014.

Sjahrir H. Nyeri Kepala. Perhimpunan Dokter Spesialis Saraf Indonesia; 2004.

Steiner TJ, Lars B. The International Classification of Headache Disorders 3rd Edition (ICHD-3) Abbreviated pocket version for reference by professional users only Title. International Headache Society; 2018.

Ferrari M, Klever R, Terwindt G, C A, van den MA. Migraine pathophysiology: lessons from mouse models and human genetics. Lancet Neurol. 2015;14(65–80).

Burstein, R ; Noseda R. Pain. Migraine patophysiology Anat trigeminovascular Pathw Assoc Neurol symptoms, cortical spreading Depress sensitization, Modul pain. 2013;S44–53.

Dodick DW. Migraine. Lancet. 2018;391(10127):1315–30.

Linde LEM. New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. Lancet. 2010;376(9741):645–55.

Schwedt T, Chiang C, Chong C, Dodick D. Functional MRI of migraine. Lancet Neurol. 2015;14:81–91.

De Felice M, Ossipov M, Wang R. Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers. Brain. 2010;133:2475–88.

Kopruszinski C, Xie J, Eyde N. Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents. Cephalalgia. 2017;37:560–70.

Diener H, Dodick D, Goadsby, Lipton R, Olesen J, Silberstein S. Chronic migraine—classification, characteristics and treatment. Nat Rev Neurol. 2012;8:162–71.

Edvinsson L. Role of CGRP. Handb Exp Pharmacol. 2019;

Lambru G, Andreou AP, Guglielmetti M, Martelletti P. Emerging drugs for migraine treatment: an update. Expert Opinion on Emerging Drugs. Expert Opin Emerg Drugs. 2018;

Raffaelli B, Neeb L, Reuter U. Monoclonal antibodies for the prevention of migraine. Expert Opinion on Biological Therapy. 2019;

Fremanezumab cost effective for migraine prevention in the US. PharmacoEcon Outcomes News. 2019;

Marta R, Irena B-B, Beata ̄yluk, Przemys3aw N, Dariusz C. The Role Of Magnesium In Migraine Pathogenesis. Potential Use of Magnesium Compounds in Prevention and Treatment of Migraine Headache. 2012;345–56.

Christina S-E, Alexander M. Expert Review. 2008;

Pringsheim T, Davenport JW, Becker WJ. Prophylaxis of migraine headache. CMAJ. 2010;182(7):E269–76.

Tepper D, Cleveland M. No Title. Am Migrain Fond. 2013;




DOI: https://doi.org/10.26618/aimj.v3i1.4154

Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Al-Iqra Medical Journal : Jurnal Berkala Ilmiah Kedokteran

Creative Commons License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.